8-KFinancial EventsOther EventsExhibits & Filings

BeOne Medicines Ltd. 8-K Report, Auditor Change (Mar 25, 2022)

Filed March 25, 2022For Securities:ONCBEIGF

Summary

This 8-K filing announces a significant change in Beigene, Ltd.'s (ONC) independent registered public accounting firm for its U.S. SEC filings. Effective March 23, 2022, Ernst & Young Hua Ming LLP, based in Beijing, has resigned. This change is attributed to the company's evolving global operations and the need for an auditor with expertise and presence aligned with its expanded international footprint, particularly in the United States. The company states there were no disagreements or reportable events with the outgoing auditor. Concurrently, the Audit Committee has appointed Ernst & Young LLP, based in Boston, Massachusetts, as the new independent registered public accounting firm for the fiscal year ending December 31, 2022. This transition aims to align the auditor with Beigene's global growth, which has seen significant expansion in operations, clinical trials, and market approvals outside of the PRC since the initial engagement of its previous auditor in 2014. The auditors for filings with the Shanghai Stock Exchange and Hong Kong Stock Exchange remain unchanged.

Key Highlights

  • 1Beigene, Ltd. (ONC) is changing its independent registered public accounting firm for SEC filings.
  • 2Ernst & Young Hua Ming LLP (Beijing) has resigned, effective March 23, 2022.
  • 3The resignation is linked to Beigene's global expansion and operational shift away from being primarily PRC-based.
  • 4No disagreements or reportable events occurred with the outgoing auditor, Ernst & Young Hua Ming LLP.
  • 5Ernst & Young LLP (Boston, Massachusetts) has been appointed as the new independent auditor for the fiscal year ending December 31, 2022.
  • 6Auditors for filings with the Shanghai and Hong Kong Stock Exchanges remain unchanged.

Frequently Asked Questions

Beigene is changing its auditor for U.S. SEC filings due to its significant global expansion since 2014. The company has grown into a global, commercial-stage biotechnology firm with operations and clinical trials spanning multiple continents, particularly in the United States. The change aims to align the U.S. SEC auditor with this expanded international footprint.

According to the filing, there were no disagreements on any matters of accounting principles or practices, financial statement disclosure, or auditing scope or procedure. Furthermore, no reportable events occurred during the fiscal years ended December 31, 2021 and 2020, or the interim period leading up to the resignation.

No, the filing explicitly states that the accounting firms auditing Beigene's financial statements filed with the Shanghai Stock Exchange (SSE) and the Hong Kong Stock Exchange (HKEx) remain unchanged. Ernst & Young Hua Ming LLP will continue to audit for the SSE filings, and Ernst & Young (Hong Kong) will continue for the HKEx filings.

Appointing Ernst & Young LLP from Boston, Massachusetts, reflects Beigene's substantial operations and focus in the United States, which is a key market for its clinical trials and commercialization efforts. This choice aligns the company's auditor for U.S. filings with its significant U.S.-based business activities.